Investment Analysts’ Recent Ratings Updates for Fortrea (FTRE)

Fortrea (NASDAQ: FTRE) has recently received a number of price target changes and ratings updates:

• 1/22/2026 – Fortrea had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 1/22/2026 – Fortrea had its price target raised by analysts at TD Cowen from $7.00 to $15.00. They now have a “hold” rating on the stock.
• 1/14/2026 – Fortrea was given a new $19.00 price target on by analysts at Robert W. Baird.
• 1/9/2026 – Fortrea was given a new $15.00 price target on by analysts at Mizuho.
• 1/8/2026 – Fortrea was given a new $22.00 price target on by analysts at Truist Financial Corporation. They now have a “buy” rating on the stock.
• 1/8/2026 – Fortrea was upgraded by analysts at Truist Financial Corporation from a “hold” rating to a “buy” rating. They now have a $22.00 price target on the stock, up previously from $12.00.
• 1/6/2026 – Fortrea was given a new $25.00 price target on by analysts at Evercore ISI. They now have an “outperform” rating on the stock.
• 1/6/2026 – Fortrea was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $25.00 price target on the stock, up previously from $14.00.
• 12/18/2025 – Fortrea had its price target raised by analysts at Mizuho from $11.00 to $13.00. They now have a “neutral” rating on the stock.
• 12/15/2025 – Fortrea was given a new $15.00 price target on by analysts at Barclays PLC. They now have an “equal weight” rating on the stock.
• 12/15/2025 – Fortrea was upgraded by analysts at Barclays PLC from an “underweight” rating to an “equal weight” rating. They now have a $15.00 price target on the stock, up previously from $10.00.
• 12/11/2025 – Fortrea was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $21.00 price target on the stock, up previously from $12.00.
• 12/11/2025 – Fortrea was given a new $21.00 price target on by analysts at Wedbush.

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.